StockNews.AI
BHC
StockNews.AI
222 days

Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb

1. Elios Vision acquired by Bausch + Lomb, enhancing their glaucoma portfolio. 2. ELIOS developed an innovative, implant-free glaucoma surgery, targeting a $2.5 billion market. 3. Over 76 million people globally affected by glaucoma need safer treatment alternatives. 4. Outcome Capital played a pivotal role in ELIOS's growth and acquisition readiness. 5. The acquisition positions ELIOS as a leader in next-generation glaucoma treatments.

M&A
+0.7%Current Return
VS
-1.52%S&P 500
$7.8301/09 09:42 AM EDTEvent Start
$7.88501/10 04:09 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

Bausch + Lomb's acquisition of ELIOS enhances its glaucoma offerings, likely boosting market perception.

How important is it?

The acquisition indicates strategic growth in the ophthalmology sector, directly impacting BHC's competitive landscape.

Why Long Term?

This acquisition potentially strengthens Bausch + Lomb's market position in glaucoma treatment over time.

Related Companies

BLCOBHC
BOSTON--(BUSINESS WIRE)--Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, which advised Elios Vision, Inc. over several years, developer of minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser, congratulates ELIOS in the success of their company, ultimately culminating in the acquisition by Bausch + Lomb Corporation (NYSE/TSX: BLCO). Over several years, Outcome has played a critical role in the inception, growth and success of ELIOS Vision. Leveraging Outcome Capital’s expertise in corporate strategy, financing, and transaction execution, the firm helped position ELIOS Vision as a key innovator in the $2.5 billion glaucoma treatment market. ELIOS Vision developed the ELIOS™ procedure, a disruptive and innovative excimer laser-based MIGS. This implant-free procedure is designed to reduce intraocular pressure (IOP) in glaucoma patients while minimizing risks associated with traditional surgeries or implant-based MIGS. ELIOS Vision’s technology is CE-marked and marketed and sold in the European Union, and is seeking U.S. Food and Drug Administration approval in the U.S this year. The procedure is versatile, performed either as a standalone treatment or alongside cataract surgery. In addition, the relative simplicity of the surgical procedure, compared with implant-based MIGS, holds the promise of a far broader adoption by surgeons. The technology also offers an opportunity to treat a significant subset of the patient population who resist implantation. Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital, commented, “Affecting over 76 million people globally, glaucoma is a devastating, complex disease, and patients are in desperate need for effective and safe alternatives to traditional treatments. At Outcome, we recognized the potential for Elios’ technology to impact patient care in 2019, when we began working together to elevate their market position. We believe this acquisition will significantly enhance Bausch + Lomb’s glaucoma portfolio and congratulate the entire Elios team on this significant accomplishment.” Outcome Capital’s involvement with ELIOS Vision exemplifies the transformative impact that specialized strategic advisory firms can have on emerging life sciences companies. By providing expert guidance during critical growth stages—ranging from financing rounds to acquisition preparation—Outcome Capital helped unlock the full potential of ELIOS Vision’s groundbreaking MIGS technology. Outcome Capital’s efforts secured funding and enhanced operational readiness, and also helped position ELIOS Vision as a leader in next-generation glaucoma treatments. “Outcome Capital helped develop a compelling narrative around ELIOS Vision’s value proposition ensuring that ELIOS was properly capitalized through multiple rounds of financing to support research and development as well as manufacturing and productization. This approach positioned ELIOS Vision as a leader in next-generation glaucoma treatments, thereby making the company an attractive acquisition target for larger players in the ophthalmology space,” commented Arnold Freedman, Managing Partner at Outcome Capital. About Outcome Capital Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.

Related News